Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone

June 14, 2025 | John Murphy | Leave a Comment

Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone

Abdel-Hameed W. Al-Mistarehi • Shadi El-Akawi • Khalid A. Kheirallah, et. al.DOI: 10.7759/cureus.67467 Abstract Background: Several medications have been proposed to manage COVID-19, with controversial data regarding their clinical benefits. We aimed to investigate the clinical…[...]

October 8, 2023 | John Murphy | Leave a Comment

Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies

Suo-wen Xu, Iqra Ilyas & Jian-ping Weng Acta Pharmacologica Sinica volume 44, pages695–709 (2023) Nature Abstract The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is still raging. However, the pathophysiology of acute and post-acute…[...]

March 28, 2022 | John Murphy | Leave a Comment

Different SARS-CoV-2 variants may give rise to different long COVID symptoms, study suggests

Italian study of long-COVID patients suggests those infected with the Alpha variant experienced different neurological and emotional symptoms compared to those who contracted the original form of SARS-CoV-2 Authors: EUROPEAN…[...]